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Abstract 
Background: to determine the levels of von 
Willebrand factor (vWF) and ADAMTS13 in patients 
of myocardial infarction and healthy controls 
Methods: In a comparative study, the samples were 
collected from 45 myocardial infarction patients and 
45 age and sex matched healthy controls. Total 5ml 
blood was collected in tri-sodium citrated vials. The 
determination of VWF was carried out by 
chromogenic assay on Stago and ADAMTS13 assay 
was carried out by standard ELISA kit. The Mann 
Whitney U test was used to determine the median 
difference between two groups (patients and 
control).  
Results; Patients with MI had higher median 
plasma level of VWF (161%) as compared to healthy 
controls (120%). The median plasma level of 
ADAMTS13 of control and patients was 56.54 U/L 
and 18.80 U/L respectively. The difference in median 
plasma levels of VWF & ADAMTS13 between 
groups was statistically significant (p < 0.001 
Conclusion: Plasma VWF and ADAMTS13 had a 
significant association with MI patients. There exists 
an inverse correlation between plasma VWF and 
ADAMTS13 levels in MI patients, but this 
correlation was very weak in control group. 
Key Words: Von Willebrand Factor, ADAMTS13, 
Myocardial Infarction, Elisa, Stago 
 
Introduction: 
VWF is a plasma glycoprotein synthesized by 
endothelial cells and megakaryocytes. Plasma VWF 
binding to platelets is important for the normal platelet 
adhesion and aggregation. The ADAMTS13 regulates 
VWF multimeric composition in the plasma by 
cleaving the large VWF multimers into smaller forms 
which are less thrombogenic. This metalloproteinase 
enzyme ADAMTS13 is synthesized mainly by 
hepatocytes, megakaryocytes and endothelial cells. 
High levels of VWF and low level of ADAMTS13 in 
the plasma are associated with an increased risk of 
recurrent Myocardial Infarction (MI).Hemostatic 
mechanism of human body relies on different factors 
and one of the most crucial ones is the Von Willebrand 
factor (VWF).1,2 It contributes significantly to 
fibrinolysis, hemostasis and regulation of vascular wall 
permeability.3  For platelet aggregation and adhesion, 
VWF is a major determinant and it acts as a bridge 
between collagen molecules of sub-endothelium at the 
site of blood vessel injury. It also serves as a carrier 
molecule for factor VIII and its plasma concentration is 
approximately 10μg/ml. 4,5  
Thrombotic diseases in human beings can take place 
due to decreased activity of ADAMTS13. 6,7 It 
circulates in plasma at a concentration of 
approximately 1 µg/ml. 8  Ultra large VWF multimers 
are absent in plasma of healthy people and remain in 
WPB. 9  After endothelial cell activation or an injury, 
these ultra large VWF multimers are discharged from 
WPB into the blood circulation. In the process of 
discharge, the ULVWF multimers transiently remains 
attached to endothelial surface, where ADAMTS13 
cleaves them into smaller as well as less active VWF 
multimers. 10  There is a high prevalence of 
spontaneous micro thrombi in the vasculature of 
patients with thrombotic thrombocytopenic purpura 
which have markedly decreased the plasma level of 
ADAMTS13. 11  ADAMTS13 plays an important role in 
an inactivation of VWF during its release.12   
Myocardial Infarction (MI) is one of the most common 
CVD manifestations. The risk factors which are more 
strongly associated with MI include hypertension, 
diabetes, hypercholesterolemia, smoking and physical 
activity.13-15 After the risk factor analysis in patients of 
myocardial Infarction (MI), it has been found that high 
plasma level of VWF are accompanied with an 
increased risk of the recurrent Myocardial Infarction 
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(MI). 16 VWF serves as a prognostic index of future 
cardiovascular risk in the general population and in 
asymptomatic patients with established coronary 
artery disease (CAD). 17  
Pathophysiologic evidence suggests that VWF is not 
only a marker but also a mediator of cardiovascular 
disease events. 18 It is produced and released by 
vascular endothelial cells in response to variety of 
stimuli which are associated with acute ischemic 
syndromes including inflammatory cytokines, 
hypoxia, thrombin and adrenaline. 19,20 Its central role 
in thrombogenesis makes it a promising target for 
research into new therapies which exclusively inhibit 
the VWF. A small number of studies have investigated 
the association of ADAMTS13 with MI by 
contradictory outcomes. The studies investigating the 
ADAMTS13 antigen levels during the acute phase (0-
14 days) of MI has observed the decreased levels of 
ADAMTS13.21  
 
Patients and Methods 
In this comparative study 90 subjects were recruited 
and divided in 2 groups .  Myocardial infarction 
patients and age and gender matched healthy 
individuals as controls. The patients above 45 years 
with first attack of myocardial infarction were 
included. These males and females patients were 
enrolled from outpatient department of Punjab 
Institute of Cardiology (PIC) Lahore with 3-6 months 
post MI history. The diagnosis was confirmed by 
taking detailed medical history, enzymes levels (T/I) 
and electrocardiogram findings. The study was 
completed in one year after approval from the ethical 
review committee and advance studies and research 
board of University of Health Sciences, Lahore. The 
patients were informed about the research and a 
written consent was taken from each enrolled patient. 
The blood samples were taken in sodium citrate vials 
and platelet poor plasma was separated by 
centrifugation for 15 min at 2500g-3000g at room 
temperature. The plasma for VWF and ADAMTS13 
were stored at -80 ˚C. The plasma was thawed at 37˚C 
for not more than 5 minutes prior to testing. Plasma 
levels of VWF were determined using commercially 
available Immuno-Turbidimetric assay of VWF (STA-
LIATEST VWF: Ag, REF 00518, Stago, France) (22). 
The plasma ADAMTS13 level was determined by 
using commercially available ELISA kit (Human 
ADAMTS13WF-cp ELISA kit, CATALOG# 12759, 
Glory Science, USA) (23). The statistical analyses were 
performed using SPSS version 20.0. 
Results 
In present study, 90 subjects were recruited, 45 
myocardial infarction patients and 45 healthy controls. 
Among 45 patients, there were 37 males and 8 females 
and in 45 healthy controls, there were 36 males 9 
females with a male to female ratio of 4:1. The mean 
age of the patients was (53.18 ± 7.75), slightly higher 
than in controls (52.04 ± 6.75) and the mean difference 
was not statistically significant (p = 0.461). The mean 
BMI of the MI patients (24.5 ± 1.4) was significantly 
higher than in controls (22.9 ±1.4) and we found 
statistically significant difference between patients and 
controls (p < 0.001) (Table-1). The clinical 
characteristics of MI patients showed that the 
hypertension (53.3%) was most commonly observed 
risk factor followed by diabetes mellitus (35.6%), 
history of smoking (20.0%) and hypercholesterolemia 
(6.7%) (Figure-2).Considering the findings related to 
plasma levels of VWF and ADAMTS13, the Mann 
Whitney U test showed that the median level of VWF 
in patients was significantly higher as compared to 
healthy controls (p < 0.000) and the median  levels of 
ADAMTS13 in patients were significantly lower as 
compared to control (p < 0.000) (Table-2). Spearman 
Rho Correlation test was used to determine the 
correlation between plasma levels of VWF and 
ADAMTS13 in both healthy controls and patients with 
MI and a significant negative correlation was found in 
MI patients (Correlation Coefficient = -0.382, p = 0.010) 
whereas, in controls, a positive and weak correlation 
was observed which was statistically not significant 
(Correlation Coefficient = 0.120, p = 0.433) (Table-3 
and Figure-3).. 
 
Table-1: Distribution of age, and BMI of study 
subjects in both groups 
 Controls Patients p-value 
Age (Years) 
Mean ± SD 
(Min–Max) 
52.04 ± 6.75 
(45 – 70) 
53.18 ± 
7.75 
(45 – 72) 
0.461 
Gender Male 36 37 >0.999 
 Female 9 8  
BMI (kg/m2) 
 
Mean ± SD 
(Min–Max) 
22.9 ±1.4 
(20.2– 25.5) 
24.5 ± 1.4 
(21.3– 27.8) 
< 0.001 
SD = Standard Deviation, BMI = Body Mass Index 
 
The Odd Ratio (OR) was significantly higher in 3rd and 
4th quartile whereas in 2nd it was on lower side for 
VWF using the 1st quartile as the reference group. We 
found an increased risk of MI in 3rd and 4th quartile 
which showed that there was a strong association of 
VWF between MI patients and controls. The OR was 
significantly higher for ADAMTS13 in 1st, 2nd and 3rd 
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quartile using the 4th quartile as the reference group. 
We found an increased risk for MI in 1st, 2nd and 3rd 
quartile which showed that there was a strong 
association of ADAMTS13 between MI patients and 
healthy controls (Table-4). Out of 45 myocardial 
infarction subjects, 9 were smokers, 23 were 
hypertensive, 15 had history of diabetes and 3 had 
high cholesterols levels 
 
Figure 1:Baseline characteristics of patients   
 
Table-2:- Comparison of Median Plasma Levels of 
VWF and ADAMTS13 in Study Subjects 
Variables 
Patients (45) Controls (45) 
Z-
score 
P-
value 
Median 
(Min-
Max) 
Median 
(Min-
Max) 
VWF 
(%) 
161.0 51-420 120.0 48-178 
-
5.021 
0.000 
ADAMTS13 
(U/L) 
18.80 
1.17-
107.78 
56.54 
3.38-
746.28 
-
4.196 
0.000 
 
Table-3: Correlation of Plasma levels of ADAMTS13 
and VWF in Patients and Controls 
Study 
Subjects 
Plasma 
level of 
VWF % 
Plasma level 
of ADAMTS13 
U/L 
Spearman 
Rho 
Correlation 
p-value 
Patients 161.0 18.80 -0.382 0.010 
Controls 120.0 56.54 0.120 0.433 
Table-4: ADAMTS13 and VWF levels in relation to 
risk of MI 
Quar-
tiles 
VWF Pat
ient
s 
Cont
rols 
Tot
al 
OR Lower Upper 
Q1 48-114 3 19 22 Ref Ref Ref 
Q2 115-141 8 15 23 3.281 0.623 17.285 
Q3 142-167 16 7 23 29.368 4.653 185.369 
Q4 168-420 18 4 22 41.217 5.679 299.167 
 Total 45 45 90    
Quar-
tiles 
ADAMTS13 
Q1 1.17 –
11.07 
16 6 22 26.667 4.727 150.428 
Q2 11.08-
35.28 
13 10 23 13.000 2.445 69.131 
Q3 35.29-
76.59 
14 9 23 15.556 2.906 83.256 
Q4 76.59-
746.28 
2 20 22 Ref Ref Ref 
 Total 45 45 90    
 
 
Figure-2: The plasma VWF levels of controls and patients were 
plotted against ADAMTS13 plasma levels. The plasma VWF & 
ADAMTS13 levels in controls (blue) and MI patients (green). A 
significant negative correlation was found in patients whereas, in 
controls, there was weak correlation in plasma levels of VWF and 
ADAMTS13. 
 
Discussion 
Myocardial infarction (MI) is the most important 
manifestation of CVDs and is one of leading cause of 
mortality.24   The outcomes have been improved in 
patients of MI with identification and management of 
modifiable risk factors. 25  The role of VWF and 
ADAMTS13 as easily measured and potentially 
modifiable risk factors has been an interesting area of 
research. The present study was done to explore the 
role of VWF and ADMATS13 as potential clinical 
markers and predictors for MI and its recurrence.   
The findings of the current study suggests that 
patients with MI have higher median plasma level of 
VWF (161.0%) as compared to healthy controls 
(120.0%). Meta-analysis of some already published 
studies has shown that higher circulating level of VWF 
is an independent risk factor for development of 
coronary artery disease (CAD). 26-28  A study on MI 
patients reported that plasma levels of VWF were 
found to be higher in patients as compared to healthy 
controls. 29  
The plasma levels of VWF were correlated with 
plasma levels of ADAMTS-13 in our group of MI 
patients, although we found a significant value (p = 
0.010) but they were inversely and very weakly 
correlated (Correlation Coefficient = -0.382). In control 
subjects, there was a positive and a weak correlation 
among plasma levels of VWF and ADAMTS-13 
(Correlation Coefficient = 0.120) but it was statistically 
not significant (p = 0.433). It means that when the 
plasma level of one variable increases, the level of 
other variable decreases and vice versa. Combined risk 
of having both high VWF and low ADAMTS13 are 
higher than that of the individual risk factor.4,21  
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Low ADAMTS13 levels are associated with MI, as is 
shown in our results and these findings are same as 
from the GLAMIS case-control study. 30  Other 
researchers did not find any association among low 
ADAMTS13 and MI. 31  Present study results showed a 
relatively weak association of low ADAMTS13 plasma 
levels with MI. Similar to that of current study, 
another study conducted in Glasgow reported, a lack 
of association between plasma levels of VWF and 
ADAMTS13 in controls. They had the opinion that 
plasma ADAMTS13 levels hardly affect plasma VWF 
levels (Crawley et al., 2011). A previous study carried 
out by Mannucci and his colleagues reported that a 
moderate degree of inverse correlation exists between 
plasma ADAMTS13 and VWF levels in MI patients. 
These findings are in line with that of current study. 32  
The findings of the current study suggests that the 
mean age of patients with MI was 53.18 ± 7.75 years.  
In a large study mean age of MI patients was 60.7±12.8 
years.33 The higher mean age of MI patients might be 
due to dietary, environmental and genetic factors of 
western populations. The reason for lower mean age of 
MI patients in our part of the world might be due to 
the consumption of more fatty diet and sedentary life 
style.  
In present study, hypertension was the most 
commonly observed clinical sign followed by diabetes 
mellitus, history of smoking and hypercholesterolemia 
in MI patients. A very large study carried out in eight 
Middle Eastern countries has reported that the 
diabetes mellitus, hypertension and 
hypercholesterolemia were attributed risk factors 
which may have driven healthy subjects towards 
cardiac diseases. 34  
In the current study subjects, hypertension was 
observed in large number of patients (53.3%). It is an 
important risk factor leading to atherogenesis and the 
development of risk plaques which turn in thrombosis 
and vessel blockage and is responsible for the 
development of acute myocardial infarction (AMI). 35  
The number of diabetic patients in present study was 
15. In diabetes mellitus, obesity is common 
particularly in type-2 diabetes mellitus and is 
associated with an increased risk of CVD. 36  Smoking 
which is attributed to ischemia may also cause the 
increment in disease burden and in this study about 
20.0% population was found to be smoker. Nicotine, 
carbon monoxide (CO) and oxidant gases of cigarette 
smoke can lead to CVD.37 The risk of atherosclerosis 
and atherosclerosis-related disorders like coronary, 
peripheral vascular and cerebrovascular diseases is 
raised in the presence of hyperlipidemia. 38-40  
Conclusion 
1.Risk of MI is increased by high VWF and low 
ADAMTS13 plasma levels and these both results 
mutually suggest that an imbalance between the 
enzyme and its substrate may plays a role in the 
formation of occlusive thrombi in a coronary artery.  
2.The ability to differentiate patient subtypes or those 
at risk of an event, on the basis of VWF levels, can be 
explored. 
  
References 
1. Peyvandi F, Garagiola I, Baronciani L. Role of von 
Willebrand factor in the haemostasis. Blood Transfusion. 
2011;9(Suppl 2):323-27. 
2. Stegner D, Nieswandt B. Platelet receptor signaling in 
thrombus formation. Journal of Molecular Mmedicine. 
2011;89(2):109-21. 
3. Hollestelle M, Lai K, van Deuren M, Lenting P, de Groot P. 
Cleavage of von Willebrand Factor by Granzyme M Destroys 
Its Factor VIII. PLOS/ONE 2011. 
4. Bongers T, de Bruijne E, Dippel D, De Jong A. Lower levels of 
ADAMTS13 are associated with cardiovascular disease in 
young patients. Atherosclerosis. 2009;207(1):250-54. 
5. Stockschlaeder M, Schneppenheim R, Budde U. Update on 
von Willebrand factor multimers. Blood Coagulation & 
Fibrinolysis. 2014;25(3):206-09. 
6. Maruyama H, Kaneko M, Otake T, Kano R. Evaluation of a 
disintegrin-like and metalloprotease with thrombospondin 
type 1 repeat motifs 13 (ADAMTS13) activity enzyme-linked 
immunosorbent assay. Journal of Veterinary Diagnostic 
Investigation. 2014;26(2):226-31. 
7. Soares A, Kazmi R, Borges M, Rosário P. Elevated plasma 
factor VIII and von Willebrand factor in women with type 2 
diabetes.British Journal of Haematology. 2013;161:33-36. 
8. Zander CB, Cao W, Zheng XL. ADAMTS13 and von 
Willebrand factor interactions. Current opinion in 
hematology. 2015;22(5):452-55. 
9. Groot E, Fijnheer R, Sebastian SA, de Groot PG. The active 
conformation of von Willebrand factor in patients with 
thrombotic thrombocytopenic purpura in remission. Journal 
of Thrombosis and Haemostasis. 2009;7(6):962-69. 
10. Gandhi C, Ahmad A, Wilson K, Chauhan A. ADAMTS13 
modulates atherosclerotic plaque progression in mice via a 
VWF dependent mechanism. Journal of Thrombosis and 
Haemostasis. 2014;12(2):255-60. 
11. Tsai H-M. Pathophysiology of thrombotic thrombocytopenic 
purpura. International journal of hematology. 
2010;91(1):1-19. 
12. Moriguchi-Goto S, Yamashita A, Tamura N, Soejima K. 
ADAMTS-13 attenuates thrombus formation on type I 
collagen surface. Atherosclerosis. 2009;203(2):409-16. 
13. Celermajer DS, Chow CK, Marijon E. Cardiovascular disease 
in the developing world: prevalences, patterns, and the 
potential of early disease detection. Journal of the American 
College of Cardiology.2012;60(14):1207-16. 
14. O'Gara PT, Kushner FG, Ascheim DD, Casey DE. ACCF/AHA 
guideline for the management of ST-elevation myocardial 
infarction. Journal of the American College of Cardiology. 
2013;61(4):e78-e140. 
15. Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A. 
Type 2 diabetes and cardiovascular disease: have all risk 
factors the same strength?World Journal of Diabetes. 
2014;5(4):444-47. 
Journal of Rawalpindi Medical College (JRMC); 2019;23(1): 25-29 
 29 
16. Wang M, Corsetti J, McNitt S, Rich DQ. Inflammatory 
markers modify the risk of recurrent coronary events 
associated with apolipoprotein AI in postinfarction patients. 
Journal of clinical lipidology. 2017;11(1):215-23. 
17. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in 
cardiovascular disease: focus on acute coronary syndromes. 
Circulation. 2008;117(11):1449-59. 
18. Koprivica Z, Djordjevic D, Vuletic M, Zivkovic V. Von 
Willebrand factor and oxidative stress parameters in acute 
coronary syndromes. Oxidative medicine and cellular 
longevity. 2011;2011. 
19. van Hinsbergh VW, editor Endothelium—role in regulation 
of coagulation and inflammation. Seminars in 
immunopathology; 2012: Springer. 
20. Badimon L, Padró T, Vilahur G. Atherosclerosis, platelets and 
thrombosis in acute ischaemic heart disease. European Heart 
Journal: Acute Cardiovascular Care. 2012;1(1):60-74. 
21. Andersson HM, Siegerink B, Luken BM, Crawley JT. High 
VWF, low ADAMTS13, and oral contraceptives increase the 
risk of ischemic stroke and myocardial infarction in young 
women. Blood. 2012;119(6):1555-60. 
22. Flood VH, editor Perils, problems, and progress in laboratory 
diagnosis of von Willebrand disease. Seminars in thrombosis 
and hemostasis; 2014: NIH Public Access. 
23. Lotta L, Valsecchi C, Pontiggia S, Mancini I, Cannavo A. 
Measurement and prevalence of circulating ADAMTS13 
specific immune complexes in autoimmune thrombotic 
thrombocytopenic purpura. Journal of Thrombosis and 
Haemostasis. 2014;12(3):329-36. 
24. Wang X, Zhao J, Zhang Y, Xue X, Yin J. Kinetics of plasma 
von Willebrand factor in acute myocardial infarction 
patients. Oncotarget. 2017;8(52):90371-74. 
25. Vernon ST, Coffey S, Bhindi R, Soo Hoo SY. Increasing 
proportion of ST elevation myocardial infarction patients 
with coronary atherosclerosis. European Journal of 
Preventive Cardiology 2017;24(17):1824-30. 
26. Whincup P, Danesh J, Walker M, Lennon L. von Willebrand 
factor and coronary heart disease. European heart journal. 
2002;23(22):1764-70. 
27. Danesh J, Wheeler JG, Hirschfield GM, Eda S. C-reactive 
protein and other circulating markers of inflammation in the 
prediction of coronary heart disease. New England Journal 
of Medicine. 2004;350(14):1387-97. 
28. Vischer U. von Willebrand factor, endothelial dysfunction, 
and cardiovascular disease. Journal of thrombosis and 
haemostasis. 2006;4(6):1186-93. 
29. Rutten B, Maseri A, Cianflone D, Laricchia A, Cristell N. 
Plasma levels of active Von Willebrand factor are increased 
in patients with first ST-segment elevation myocardial 
infarction. European Heart Journal: Acute Cardiovascular 
Care. 2015;4(1):64-74. 
30. Crawley JT, de Groot R, Xiang Y, Luken BM, Lane DA. 
Unraveling the scissile bond: how ADAMTS13 recognizes 
and cleaves von Willebrand factor. Blood. 
2011;118(12):3212-21. 
31. Chion CK, Doggen CJ, Crawley JT, Lane DA. ADAMTS13 and 
von Willebrand factor and the risk of myocardial infarction 
in men. Blood. 2007;109(5):1998-2000. 
32. Mannucci PM, Capoferri C, Canciani MT. Plasma levels of 
von Willebrand factor regulate ADAMTS13, its major 
cleaving protease. British Journal of Haematology. 
2004;126(2):213-18. 
33. Iversen B, Jacobsen BK, Løchen M-L. Active and passive 
smoking and the risk of myocardial infarction in 24,968 
men and women during 11 year of follow-up. European 
journal of epidemiology. 2013;28(8):659-67. 
34. Gehani AA, Al-Hinai AT, Zubaid M, Almahmeed W. 
Association of risk factors with acute myocardial infarction 
in Middle Eastern countries. European Journal of Preventive 
Cardiology. 2014;21(4):400-10. 
35. Picariello C, Lazzeri C, Attana P, Chiostri M. The impact of 
hypertension on patients with acute coronary syndromes. 
International journal of hypertension. 2011;2011. 
36. Leon BM, Maddox TM. Diabetes and cardiovascular disease: 
Epidemiology, biological mechanisms, treatment 
recommendations and future research. World journal of 
diabetes. 2015;6(13):1246-49. 
37. George P. Effects of smoking on cardiovascular function: the 
role of nicotine and carbon monoxide. Health science 
journal. 2014;8(2):202-05. 
38. Arboix A. Cardiovascular risk factors for acute stroke: Risk 
profiles in the different subtypes of ischemic stroke. World 
Journal of Clinical Cases: WJCC. 2015;3(5):418-22. 
39. Shattat GF. A review article on hyperlipidemia: types, 
treatments and new drug targets. Biomedical and 
Pharmacology Journal. 2015;7(1):399-409. 
40. Rafieian-Kopaei M, Setorki M, Doudi M, Baradaran A. 
Atherosclerosis: process, indicators, risk factors and new 
hopes.International journal of preventive medicine. 
2014;5(8):927-31. 
 
Contribution of Authors: Shamila Tahir=A,B,C,F; Nazish Mazari 
= A,B,D; Aisha Chauhdry =A,BC; Ghulma Mustafa=C,F; Shahida 
Mohsin=A,B,E,F 
Key for Contribution of Authors : A= Conception/ Study/ 
Designing /Planning; B= Experimentation/Study 
conduction;C=Analysis/Interpretation/ Discussion; D= 
Manuscript writing;E= Critical review;F= Facilitated for 
reagents/Material/Analysis 
 
 
 
